Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 19 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Venetoclax in combination with a hypomethylating agent or low dose cytarabine for newly diagnosed acute myeloid leukaemia	hypomethylating agent , Low-dose cytarabine , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Treosulfan in combination with Fludarabine for Malignant and Non-Malignant diseases - prior to stem cell transplantation	Fludarabine (fludarabine phosphate) , Treosulfan (Ovastat)	Acute myeloid leukaemia (AML) , Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2018	View \| Download
Quizartinib with chemotherapy for FLT3-ITD positive acute myeloid leukaemia	Quizartinib (AC220)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2021	View \| Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation	Melphalan hydrochloride (Cydex; CDX-353; Phelinun)	Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer	Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer	2021	View \| Download
Pevonedistat in addition to azacitidine for Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low Blast Acute Myeloid Leukemia – first-line	Azacitidine (Vidaza; CC-486) , Pevonedistat (MLN-4924; TAK-924)	Acute myeloid leukaemia (AML) , Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2020	View \| Download
Liposomal cytarabine-daunorubicin for treating relapsed or refractory acute myeloid leukaemia in paediatric patients.	CPX-351 (Vyxeos Liposomal) (fixed dose combination: Cytarabine; daunorubicin)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2020	View \| Download
Ivosidenib with azacitidine for previously untreated acute myeloid leukaemia with an IDH1 mutation	Azacitidine (Vidaza; CC-486) , Ivosidenib (Tibsovo; AG-120)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2022	View \| Download
Ivosidenib for acute myeloid leukaemia with IDH1 mutation	Ivosidenib (Tibsovo; AG-120)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older)	I-131-Apamistamab (Iomab-B)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2017	View \| Download
Idasanutlin in addition to cytarabine for relapsed or refractory acute myeloid leukaemia	Cytarabine , Idasanutlin (RG7388; RO5503781)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2019	View \| Download